Adial Pharmaceuticals, Inc. Sale of Stock, Consideration Received on Transaction
Adial Pharmaceuticals, Inc. (ADIL) reported Sale of Stock, Consideration Received on Transaction of $4.90 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-08.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2026-05-08
- Adial Pharmaceuticals, Inc. sale of stock, consideration received on transaction for the quarter ending 2026-03-31 was $4.90M, a 0.00% change year-over-year.
- Adial Pharmaceuticals, Inc. sale of stock, consideration received on transaction for the quarter ending 2025-12-31 was $0.00.
- Adial Pharmaceuticals, Inc. sale of stock, consideration received on transaction for the quarter ending 2025-09-30 was $0.00.
- Adial Pharmaceuticals, Inc. sale of stock, consideration received on transaction for the quarter ending 2025-06-30 was $0.00.
- Adial Pharmaceuticals, Inc. sale of stock, consideration received on transaction for fiscal 2025 was $4.90M.
| Period end | Sale of Stock, Consideration Received on Transaction | Sale of Stock, Consideration Received on Transaction 1 month | Sale of Stock, Consideration Received on Transaction 3 month | Sale of Stock, Consideration Received on Transaction 6 month | Sale of Stock, Consideration Received on Transaction 9 month | Sale of Stock, Consideration Received on Transaction 12 month |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4.90M 10-Q · filed 2026-05-08 | $4.90M derived: sum of 2 quarters · filed 2026-05-08 | $4.90M derived: sum of 3 quarters · filed 2026-05-08 | $4.90M derived: sum of 4 quarters · filed 2026-05-08 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $4.90M 10-K · filed 2026-03-05 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $4.90M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $4.90M 10-Q · filed 2025-08-13 | ||||
| 2025-03-31 | $4.90M 10-Q · filed 2025-05-14 | |||||
| 2024-03-01 | $3.50M 10-Q · filed 2024-11-13 | |||||
| 2021-01-26 | $1.06M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |